MT3抗体—艾普蒂

The MT3 antibody targets metallothionein-3 (MT3), a small, cysteine-rich protein primarily expressed in the central nervous system (CNS). Metallothioneins (MTs) are a family of metal-binding proteins involved in zinc and copper homeostasis, detoxification of heavy metals, and protection against oxidative stress. Unlike other isoforms (e.g., MT1/2), MT3 is neuron-specific and was initially identified as a growth inhibitory factor in Alzheimer’s disease (AD) due to its reduced levels in AD brains. MT3 binds zinc ions with high affinity, modulating synaptic zinc availability and influencing neurotrophic signaling pathways. It also plays roles in neuroprotection, mitigating oxidative damage, and regulating inflammatory responses in neurodegenerative conditions. MT3 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological states. Research applications include immunohistochemistry, Western blotting, and ELISA to explore MT3's involvement in diseases like Parkinson’s, ALS, and AD. Additionally, these antibodies aid in elucidating MT3's dual role—acting as a neuroprotectant under stress while potentially contributing to metal dyshomeostasis in neurodegeneration. Understanding MT3 dynamics through antibody-based assays remains critical for developing therapeutic strategies targeting metal-related neurological disorders.